![Tom Holgate](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tom Holgate
Directeur/Membre du Conseil chez BenevolentAI Cambridge Ltd.
Profil
Tom Joseph Charles Holgate is currently a Director at BenevolentAI Cambridge Ltd.
and BenevolentAI Technology Ltd.
He previously worked as a Senior Vice President & Group Finance Director at BenevolentAI SA.
Postes actifs de Tom Holgate
Sociétés | Poste | Début |
---|---|---|
BenevolentAI Cambridge Ltd.
![]() BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 21/02/2018 |
BenevolentAI Technology Ltd.
![]() BenevolentAI Technology Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Technology Ltd. is a leading, clinical-stage AI-enabled drug discovery and British development company. Founded in 2005, the company is based in London, UK. From target identification through to clinical development, their AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success. The company uses AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. The company uses machine learning to generate new insights into the underlying causes of disease and capture these insights in their knowledge graph to support drug discovery and development. In 2022, they refined and formalized their approach to sustainability, under the direction of the newly established environmental, social and governance (ESG) governance structure and teams. | Directeur/Membre du Conseil | 29/05/2019 |
Anciens postes connus de Tom Holgate
Sociétés | Poste | Fin |
---|---|---|
BENEVOLENTAI | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BENEVOLENTAI | Health Technology |
Entreprise privées | 2 |
---|---|
BenevolentAI Cambridge Ltd.
![]() BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
BenevolentAI Technology Ltd.
![]() BenevolentAI Technology Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Technology Ltd. is a leading, clinical-stage AI-enabled drug discovery and British development company. Founded in 2005, the company is based in London, UK. From target identification through to clinical development, their AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success. The company uses AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. The company uses machine learning to generate new insights into the underlying causes of disease and capture these insights in their knowledge graph to support drug discovery and development. In 2022, they refined and formalized their approach to sustainability, under the direction of the newly established environmental, social and governance (ESG) governance structure and teams. | Technology Services |